Teva Brings First GLP-1 Generic for Obesity, Targets Novo’s Saxenda
In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.
Teva Brings First GLP-1 Generic for Obesity, Targets Novo’s Saxenda Read More »
